Pfizer Scores Broad Label For Talzenna/Xtandi In Valuable First-Line Prostate Cancer Indication

Pfizer Inc. stands to gain significantly from the approval of its PARP inhibitor Talzenna (talazoparib) in combination with the anti-androgen drug Xtandi (enzalutamide) thanks to both drugs being under its umbrella – it has a partnership with Astellas Pharma, Inc. for Xtandi – as well as a label for one of its main competitors that turned out narrower than expected. The Pfizer approval thus gives Talzenna/Xtandi a potentially big advantage in a field that will likely include three players competing in the same market.

The US Food and Drug Administration approved the combination of Talzenna/Xtandi on 20 June for metastatic castration-resistant prostate cancer (mCRPC)...